about
Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndromeEndocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controlsGuidance on reporting ultrasound exposure conditions for bio-effects studies.Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.Atorvastatin increases 25-hydroxy vitamin D concentrations in patients with polycystic ovary syndrome.Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.The effect of atorvastatin on pancreatic beta cell requirement in women with polycystic ovary syndrome.Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.Hyponatraemia secondary to cerebral salt wasting syndrome following routine pituitary surgery.Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.Insulin resistance variability in women with anovulatory and ovulatory polycystic ovary syndrome, and normal controls.Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.Multiple cerebral haematomata and peripheral nerve palsies associated with a case of juvenile diabetic ketoacidosisDiagnosis and management of uterine arterio-venous malformationsAtorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled studyTwin pregnancy with a complete hydatidiform mole and co-existent healthy fetus: unusual case of complete resorption of molar pregnancy
P50
Q33705831-73769ECC-73E2-4A3B-B1A0-33633EF3E6B5Q33908763-176A1BA8-5E30-4524-9B9B-8D4EF24B1847Q35312833-88AF0F35-0891-4CA6-8E50-343999FEFFBAQ37831660-C83D9076-A092-4AC2-AFB7-6852E7336E89Q38960268-DDE4973F-1445-4C2E-A9A1-9A4DD0093B44Q42917429-DA3328D6-C8D8-4496-8902-9A98D2B20FA5Q45169384-4B494BE4-D11B-4300-A8EE-1D96BA725662Q46172452-B78985A7-327E-4959-8219-9837B3FDA29FQ46305285-F90FAB45-2CFA-4420-966F-785FB2FB5F3BQ46545539-D73D96D8-930D-4566-8ECC-A9C2E6762C66Q46646075-03C7C90E-ADFC-457B-A266-DE5A3D5621A2Q47143029-7A944BB5-0C1B-4ADC-904E-19417949D1B1Q48214412-1AAF0734-A861-47B7-95E3-423F7F7EFAE2Q48954688-95945F70-7535-41F4-85F1-BA245A06A3C2Q51328922-ACDD4590-1AAB-4BAF-808E-C19D9C2C9FD0Q51381802-826C50C0-2042-46A6-8AE5-9FD19731B94EQ64951371-EE0D6376-90BB-484D-A131-5DFA122E6D10Q72256688-5496F8B0-EE94-4A47-AEE3-29CD749CC217Q77346834-2E442D6A-AF34-46E2-8ADB-5F57DF3EB132Q85043105-35D10232-873C-4B3D-BF3C-FF8B5FB12C9BQ86527374-C9505555-70B8-4EE9-9400-B87CFCD707D5
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Anne M Coady
@nl
Anne M Coady
@sl
Anne M. Coady
@en
Anne M. Coady
@es
type
label
Anne M Coady
@nl
Anne M Coady
@sl
Anne M. Coady
@en
Anne M. Coady
@es
prefLabel
Anne M Coady
@nl
Anne M Coady
@sl
Anne M. Coady
@en
Anne M. Coady
@es
P106
P1153
6701920155
P21
P31
P496
0000-0003-3304-8644